Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

SUMMARY The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD) was funded as part of a National Institute of Mental Health initiative to develop effectiveness information about treatments, illness course, and assessment strategies for severe mental disorders. STEP‐BD studies wer...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:CNS neuroscience & therapeutics 2012-03, Vol.18 (3), p.243-249
Hauptverfasser: Bowden, C.L., Perlis, R.H., Thase, M.E., Ketter, T.A., Ostacher, M.M., Calabrese, J.R., Reilly-Harrington, N.A., Gonzalez, J.M., Singh, V., Nierenberg, A.A., Sachs, G.S.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 249
container_issue 3
container_start_page 243
container_title CNS neuroscience & therapeutics
container_volume 18
creator Bowden, C.L.
Perlis, R.H.
Thase, M.E.
Ketter, T.A.
Ostacher, M.M.
Calabrese, J.R.
Reilly-Harrington, N.A.
Gonzalez, J.M.
Singh, V.
Nierenberg, A.A.
Sachs, G.S.
description SUMMARY The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD) was funded as part of a National Institute of Mental Health initiative to develop effectiveness information about treatments, illness course, and assessment strategies for severe mental disorders. STEP‐BD studies were planned to be generalizable both to the research knowledge base for bipolar disorder and to clinical care of bipolar patients. Several novel methodologies were developed to aid in illness characterization, and were combined with existing scales on function, quality of life, illness burden, adherence, adverse effects, and temperament to yield a comprehensive data set. The methods integrated naturalistic treatment and randomized clinical trials, which a portion of STEP‐BD participants participated. All investigators and other researchers in this multisite program were trained in a collaborative care model with the objective of retaining a high percentage of enrollees for several years. Articles from STEP‐BD have yielded evidence on risk factors impacting outcomes, suicidality, functional status, recovery, relapse, and caretaker burden. The findings from these studies brought into question the widely practiced use of antidepressants in bipolar depression as well as substantiated the poorly responsive course of bipolar depression despite use of combination strategies. In particular, large studies on the characteristics and course of bipolar depression (the more pervasive pole of the illness), and the outcomes of treatments concluded that adjunctive psychosocial treatments but not adjunctive antidepressants yielded outcomes superior to those achieved with mood stabilizers alone. The majority of patients with bipolar depression concurrently had clinically significant manic symptoms. Anxiety, smoking, and early age of bipolar onset were each associated with increased illness burden. STEP‐BD has established procedures that are relevant to future collaborative research programs aimed at the systematic study of the complex, intrinsically important elements of bipolar disorders.
doi_str_mv 10.1111/j.1755-5949.2011.00257.x
format Article
fullrecord <record><control><sourceid>proquest_24P</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6493527</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2399395674</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6657-8ea2712aee61f4ad272a7c91e2a62d249ace058f3602f4f703fa29a81d290fce3</originalsourceid><addsrcrecordid>eNqNkl1v0zAUhiMEYmPwF5AlLhgXCf6IvySEtHVlnejKoEXjzjKJs7okcbFTaP89zjoi4GLCNz7Sed5X9jlvkgAEMxTP61WGOKUplbnMMEQogxBTnm0fJIdD4-FQE3iQPAlhBSHDQorHyQHGkEOao8OkPLFNALotwScTNnUXgKtAtzRgdnE5AfNd6EyjO1uAhTe6a0zbgXG71G1hbusr7268bkDlPDi1a1drD85scL40HhzPF-Or9PTs1dPkUaXrYJ7d3UfJ53fjxWiSTj-cX4xOpmnBGOWpMBpzhLUxDFW5LjHHmhcSGawZLnEudWEgFRVhEFd5xSGpNJZaoBJLWBWGHCVv977rzdfGlEV8ode1WnvbaL9TTlv1d6e1S3XjfiiWS0IxjwYv7wy8-74xoVONDYWpa90atwlKMoE4wQhF8vheEsWtICmibURf_IOu3Ma3cRAKEymJpIzn91JYEIkElD0l9lThXQjeVMPnEFR9NNRK9VtXfQJUHw11Gw21jdLnfw5nEP7OQgTe7IGftja7_zZWo9k8FlGe7uU2ZmY7yLX_phgnnKrr2bm6fH9NJ1P6UX0hvwD6gNS6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2283918094</pqid></control><display><type>article</type><title>Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)</title><source>Wiley Online Library Open Access</source><creator>Bowden, C.L. ; Perlis, R.H. ; Thase, M.E. ; Ketter, T.A. ; Ostacher, M.M. ; Calabrese, J.R. ; Reilly-Harrington, N.A. ; Gonzalez, J.M. ; Singh, V. ; Nierenberg, A.A. ; Sachs, G.S.</creator><creatorcontrib>Bowden, C.L. ; Perlis, R.H. ; Thase, M.E. ; Ketter, T.A. ; Ostacher, M.M. ; Calabrese, J.R. ; Reilly-Harrington, N.A. ; Gonzalez, J.M. ; Singh, V. ; Nierenberg, A.A. ; Sachs, G.S.</creatorcontrib><description>SUMMARY The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD) was funded as part of a National Institute of Mental Health initiative to develop effectiveness information about treatments, illness course, and assessment strategies for severe mental disorders. STEP‐BD studies were planned to be generalizable both to the research knowledge base for bipolar disorder and to clinical care of bipolar patients. Several novel methodologies were developed to aid in illness characterization, and were combined with existing scales on function, quality of life, illness burden, adherence, adverse effects, and temperament to yield a comprehensive data set. The methods integrated naturalistic treatment and randomized clinical trials, which a portion of STEP‐BD participants participated. All investigators and other researchers in this multisite program were trained in a collaborative care model with the objective of retaining a high percentage of enrollees for several years. Articles from STEP‐BD have yielded evidence on risk factors impacting outcomes, suicidality, functional status, recovery, relapse, and caretaker burden. The findings from these studies brought into question the widely practiced use of antidepressants in bipolar depression as well as substantiated the poorly responsive course of bipolar depression despite use of combination strategies. In particular, large studies on the characteristics and course of bipolar depression (the more pervasive pole of the illness), and the outcomes of treatments concluded that adjunctive psychosocial treatments but not adjunctive antidepressants yielded outcomes superior to those achieved with mood stabilizers alone. The majority of patients with bipolar depression concurrently had clinically significant manic symptoms. Anxiety, smoking, and early age of bipolar onset were each associated with increased illness burden. STEP‐BD has established procedures that are relevant to future collaborative research programs aimed at the systematic study of the complex, intrinsically important elements of bipolar disorders.</description><identifier>ISSN: 1755-5930</identifier><identifier>ISSN: 1755-5949</identifier><identifier>EISSN: 1755-5949</identifier><identifier>DOI: 10.1111/j.1755-5949.2011.00257.x</identifier><identifier>PMID: 22070541</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Age ; Alcohol use ; Antidepressants ; Antidepressive Agents - therapeutic use ; Anxiety ; Anxiety disorders ; Bipolar ; Bipolar disorder ; Bipolar Disorder - diagnosis ; Bipolar Disorder - psychology ; Bipolar Disorder - therapy ; Central nervous system ; Clinical trials ; Collaboration ; Comorbidity ; Data processing ; Depression ; Drug use ; Eating disorders ; Humans ; Illnesses ; Longitudinal studies ; Mental depression ; Mental disorders ; Mood ; Mood Disorders ; National Institute of Mental Health (U.S.) - trends ; Nervous system ; Neuropsychopharmacology ; Patients ; Personality ; Quality of life ; Randomized Controlled Trials as Topic - methods ; Recovery of function ; Research programs ; Review ; Reviews (Special Issue for Bipolar Disorder) ; Risk factors ; Side effects ; Sleep ; Smoking ; Suicides &amp; suicide attempts ; Treatment ; Treatment Outcome ; United States</subject><ispartof>CNS neuroscience &amp; therapeutics, 2012-03, Vol.18 (3), p.243-249</ispartof><rights>2011 Blackwell Publishing Ltd</rights><rights>2011 Blackwell Publishing Ltd.</rights><rights>Copyright Wiley Subscription Services, Inc. Mar 2012</rights><rights>Copyright John Wiley &amp; Sons, Inc. Mar 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c6657-8ea2712aee61f4ad272a7c91e2a62d249ace058f3602f4f703fa29a81d290fce3</citedby><cites>FETCH-LOGICAL-c6657-8ea2712aee61f4ad272a7c91e2a62d249ace058f3602f4f703fa29a81d290fce3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493527/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6493527/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,11541,27901,27902,45550,45551,46027,46451,53766,53768</link.rule.ids><linktorsrc>$$Uhttps://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1755-5949.2011.00257.x$$EView_record_in_Wiley-Blackwell$$FView_record_in_$$GWiley-Blackwell</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22070541$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bowden, C.L.</creatorcontrib><creatorcontrib>Perlis, R.H.</creatorcontrib><creatorcontrib>Thase, M.E.</creatorcontrib><creatorcontrib>Ketter, T.A.</creatorcontrib><creatorcontrib>Ostacher, M.M.</creatorcontrib><creatorcontrib>Calabrese, J.R.</creatorcontrib><creatorcontrib>Reilly-Harrington, N.A.</creatorcontrib><creatorcontrib>Gonzalez, J.M.</creatorcontrib><creatorcontrib>Singh, V.</creatorcontrib><creatorcontrib>Nierenberg, A.A.</creatorcontrib><creatorcontrib>Sachs, G.S.</creatorcontrib><title>Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)</title><title>CNS neuroscience &amp; therapeutics</title><addtitle>CNS Neurosci Ther</addtitle><description>SUMMARY The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD) was funded as part of a National Institute of Mental Health initiative to develop effectiveness information about treatments, illness course, and assessment strategies for severe mental disorders. STEP‐BD studies were planned to be generalizable both to the research knowledge base for bipolar disorder and to clinical care of bipolar patients. Several novel methodologies were developed to aid in illness characterization, and were combined with existing scales on function, quality of life, illness burden, adherence, adverse effects, and temperament to yield a comprehensive data set. The methods integrated naturalistic treatment and randomized clinical trials, which a portion of STEP‐BD participants participated. All investigators and other researchers in this multisite program were trained in a collaborative care model with the objective of retaining a high percentage of enrollees for several years. Articles from STEP‐BD have yielded evidence on risk factors impacting outcomes, suicidality, functional status, recovery, relapse, and caretaker burden. The findings from these studies brought into question the widely practiced use of antidepressants in bipolar depression as well as substantiated the poorly responsive course of bipolar depression despite use of combination strategies. In particular, large studies on the characteristics and course of bipolar depression (the more pervasive pole of the illness), and the outcomes of treatments concluded that adjunctive psychosocial treatments but not adjunctive antidepressants yielded outcomes superior to those achieved with mood stabilizers alone. The majority of patients with bipolar depression concurrently had clinically significant manic symptoms. Anxiety, smoking, and early age of bipolar onset were each associated with increased illness burden. STEP‐BD has established procedures that are relevant to future collaborative research programs aimed at the systematic study of the complex, intrinsically important elements of bipolar disorders.</description><subject>Age</subject><subject>Alcohol use</subject><subject>Antidepressants</subject><subject>Antidepressive Agents - therapeutic use</subject><subject>Anxiety</subject><subject>Anxiety disorders</subject><subject>Bipolar</subject><subject>Bipolar disorder</subject><subject>Bipolar Disorder - diagnosis</subject><subject>Bipolar Disorder - psychology</subject><subject>Bipolar Disorder - therapy</subject><subject>Central nervous system</subject><subject>Clinical trials</subject><subject>Collaboration</subject><subject>Comorbidity</subject><subject>Data processing</subject><subject>Depression</subject><subject>Drug use</subject><subject>Eating disorders</subject><subject>Humans</subject><subject>Illnesses</subject><subject>Longitudinal studies</subject><subject>Mental depression</subject><subject>Mental disorders</subject><subject>Mood</subject><subject>Mood Disorders</subject><subject>National Institute of Mental Health (U.S.) - trends</subject><subject>Nervous system</subject><subject>Neuropsychopharmacology</subject><subject>Patients</subject><subject>Personality</subject><subject>Quality of life</subject><subject>Randomized Controlled Trials as Topic - methods</subject><subject>Recovery of function</subject><subject>Research programs</subject><subject>Review</subject><subject>Reviews (Special Issue for Bipolar Disorder)</subject><subject>Risk factors</subject><subject>Side effects</subject><subject>Sleep</subject><subject>Smoking</subject><subject>Suicides &amp; suicide attempts</subject><subject>Treatment</subject><subject>Treatment Outcome</subject><subject>United States</subject><issn>1755-5930</issn><issn>1755-5949</issn><issn>1755-5949</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkl1v0zAUhiMEYmPwF5AlLhgXCf6IvySEtHVlnejKoEXjzjKJs7okcbFTaP89zjoi4GLCNz7Sed5X9jlvkgAEMxTP61WGOKUplbnMMEQogxBTnm0fJIdD4-FQE3iQPAlhBSHDQorHyQHGkEOao8OkPLFNALotwScTNnUXgKtAtzRgdnE5AfNd6EyjO1uAhTe6a0zbgXG71G1hbusr7268bkDlPDi1a1drD85scL40HhzPF-Or9PTs1dPkUaXrYJ7d3UfJ53fjxWiSTj-cX4xOpmnBGOWpMBpzhLUxDFW5LjHHmhcSGawZLnEudWEgFRVhEFd5xSGpNJZaoBJLWBWGHCVv977rzdfGlEV8ode1WnvbaL9TTlv1d6e1S3XjfiiWS0IxjwYv7wy8-74xoVONDYWpa90atwlKMoE4wQhF8vheEsWtICmibURf_IOu3Ma3cRAKEymJpIzn91JYEIkElD0l9lThXQjeVMPnEFR9NNRK9VtXfQJUHw11Gw21jdLnfw5nEP7OQgTe7IGftja7_zZWo9k8FlGe7uU2ZmY7yLX_phgnnKrr2bm6fH9NJ1P6UX0hvwD6gNS6</recordid><startdate>201203</startdate><enddate>201203</enddate><creator>Bowden, C.L.</creator><creator>Perlis, R.H.</creator><creator>Thase, M.E.</creator><creator>Ketter, T.A.</creator><creator>Ostacher, M.M.</creator><creator>Calabrese, J.R.</creator><creator>Reilly-Harrington, N.A.</creator><creator>Gonzalez, J.M.</creator><creator>Singh, V.</creator><creator>Nierenberg, A.A.</creator><creator>Sachs, G.S.</creator><general>Blackwell Publishing Ltd</general><general>John Wiley &amp; Sons, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>201203</creationdate><title>Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)</title><author>Bowden, C.L. ; Perlis, R.H. ; Thase, M.E. ; Ketter, T.A. ; Ostacher, M.M. ; Calabrese, J.R. ; Reilly-Harrington, N.A. ; Gonzalez, J.M. ; Singh, V. ; Nierenberg, A.A. ; Sachs, G.S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6657-8ea2712aee61f4ad272a7c91e2a62d249ace058f3602f4f703fa29a81d290fce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Age</topic><topic>Alcohol use</topic><topic>Antidepressants</topic><topic>Antidepressive Agents - therapeutic use</topic><topic>Anxiety</topic><topic>Anxiety disorders</topic><topic>Bipolar</topic><topic>Bipolar disorder</topic><topic>Bipolar Disorder - diagnosis</topic><topic>Bipolar Disorder - psychology</topic><topic>Bipolar Disorder - therapy</topic><topic>Central nervous system</topic><topic>Clinical trials</topic><topic>Collaboration</topic><topic>Comorbidity</topic><topic>Data processing</topic><topic>Depression</topic><topic>Drug use</topic><topic>Eating disorders</topic><topic>Humans</topic><topic>Illnesses</topic><topic>Longitudinal studies</topic><topic>Mental depression</topic><topic>Mental disorders</topic><topic>Mood</topic><topic>Mood Disorders</topic><topic>National Institute of Mental Health (U.S.) - trends</topic><topic>Nervous system</topic><topic>Neuropsychopharmacology</topic><topic>Patients</topic><topic>Personality</topic><topic>Quality of life</topic><topic>Randomized Controlled Trials as Topic - methods</topic><topic>Recovery of function</topic><topic>Research programs</topic><topic>Review</topic><topic>Reviews (Special Issue for Bipolar Disorder)</topic><topic>Risk factors</topic><topic>Side effects</topic><topic>Sleep</topic><topic>Smoking</topic><topic>Suicides &amp; suicide attempts</topic><topic>Treatment</topic><topic>Treatment Outcome</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bowden, C.L.</creatorcontrib><creatorcontrib>Perlis, R.H.</creatorcontrib><creatorcontrib>Thase, M.E.</creatorcontrib><creatorcontrib>Ketter, T.A.</creatorcontrib><creatorcontrib>Ostacher, M.M.</creatorcontrib><creatorcontrib>Calabrese, J.R.</creatorcontrib><creatorcontrib>Reilly-Harrington, N.A.</creatorcontrib><creatorcontrib>Gonzalez, J.M.</creatorcontrib><creatorcontrib>Singh, V.</creatorcontrib><creatorcontrib>Nierenberg, A.A.</creatorcontrib><creatorcontrib>Sachs, G.S.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>CNS neuroscience &amp; therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bowden, C.L.</au><au>Perlis, R.H.</au><au>Thase, M.E.</au><au>Ketter, T.A.</au><au>Ostacher, M.M.</au><au>Calabrese, J.R.</au><au>Reilly-Harrington, N.A.</au><au>Gonzalez, J.M.</au><au>Singh, V.</au><au>Nierenberg, A.A.</au><au>Sachs, G.S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)</atitle><jtitle>CNS neuroscience &amp; therapeutics</jtitle><addtitle>CNS Neurosci Ther</addtitle><date>2012-03</date><risdate>2012</risdate><volume>18</volume><issue>3</issue><spage>243</spage><epage>249</epage><pages>243-249</pages><issn>1755-5930</issn><issn>1755-5949</issn><eissn>1755-5949</eissn><abstract>SUMMARY The Systematic Treatment Enhancement Program for Bipolar Disorder (STEP‐BD) was funded as part of a National Institute of Mental Health initiative to develop effectiveness information about treatments, illness course, and assessment strategies for severe mental disorders. STEP‐BD studies were planned to be generalizable both to the research knowledge base for bipolar disorder and to clinical care of bipolar patients. Several novel methodologies were developed to aid in illness characterization, and were combined with existing scales on function, quality of life, illness burden, adherence, adverse effects, and temperament to yield a comprehensive data set. The methods integrated naturalistic treatment and randomized clinical trials, which a portion of STEP‐BD participants participated. All investigators and other researchers in this multisite program were trained in a collaborative care model with the objective of retaining a high percentage of enrollees for several years. Articles from STEP‐BD have yielded evidence on risk factors impacting outcomes, suicidality, functional status, recovery, relapse, and caretaker burden. The findings from these studies brought into question the widely practiced use of antidepressants in bipolar depression as well as substantiated the poorly responsive course of bipolar depression despite use of combination strategies. In particular, large studies on the characteristics and course of bipolar depression (the more pervasive pole of the illness), and the outcomes of treatments concluded that adjunctive psychosocial treatments but not adjunctive antidepressants yielded outcomes superior to those achieved with mood stabilizers alone. The majority of patients with bipolar depression concurrently had clinically significant manic symptoms. Anxiety, smoking, and early age of bipolar onset were each associated with increased illness burden. STEP‐BD has established procedures that are relevant to future collaborative research programs aimed at the systematic study of the complex, intrinsically important elements of bipolar disorders.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>22070541</pmid><doi>10.1111/j.1755-5949.2011.00257.x</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier ISSN: 1755-5930
ispartof CNS neuroscience & therapeutics, 2012-03, Vol.18 (3), p.243-249
issn 1755-5930
1755-5949
1755-5949
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6493527
source Wiley Online Library Open Access
subjects Age
Alcohol use
Antidepressants
Antidepressive Agents - therapeutic use
Anxiety
Anxiety disorders
Bipolar
Bipolar disorder
Bipolar Disorder - diagnosis
Bipolar Disorder - psychology
Bipolar Disorder - therapy
Central nervous system
Clinical trials
Collaboration
Comorbidity
Data processing
Depression
Drug use
Eating disorders
Humans
Illnesses
Longitudinal studies
Mental depression
Mental disorders
Mood
Mood Disorders
National Institute of Mental Health (U.S.) - trends
Nervous system
Neuropsychopharmacology
Patients
Personality
Quality of life
Randomized Controlled Trials as Topic - methods
Recovery of function
Research programs
Review
Reviews (Special Issue for Bipolar Disorder)
Risk factors
Side effects
Sleep
Smoking
Suicides & suicide attempts
Treatment
Treatment Outcome
United States
title Aims and Results of the NIMH Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T14%3A25%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_24P&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Aims%20and%20Results%20of%20the%20NIMH%20Systematic%20Treatment%20Enhancement%20Program%20for%20Bipolar%20Disorder%20(STEP-BD)&rft.jtitle=CNS%20neuroscience%20&%20therapeutics&rft.au=Bowden,%20C.L.&rft.date=2012-03&rft.volume=18&rft.issue=3&rft.spage=243&rft.epage=249&rft.pages=243-249&rft.issn=1755-5930&rft.eissn=1755-5949&rft_id=info:doi/10.1111/j.1755-5949.2011.00257.x&rft_dat=%3Cproquest_24P%3E2399395674%3C/proquest_24P%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2283918094&rft_id=info:pmid/22070541&rfr_iscdi=true